Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Microarrays Aim for Center Stage

This article was originally published in Start Up

Executive Summary

Accepted in discovery, microarrays are paving the way for biomarker development and eventually, molecular diagnostics.

You may also be interested in...

Spectral Genomics Inc.

Spectral Genomics Inc., aims to become one of the first, if not the first, to bring a diagnostic microarray through to FDA approval. Spectral belives its BAC clone arrays offer major advantages in detecting large scale chromosomal amplifications, deletions and rearrangements characteristic of cancers and many congenital defects. The speed and universality of the arrays make them potentially practical for low-cost, high-speed, and targeted diagnostic purposes.

Agilix Corp.

Mid-stage clinical trial data rarely provide an easy answer on whether to advance a compound into complex and costly pivotal studies. Agilix Corp. has stepped into that void to offer gene expression analysis services using its GenCompass-a microarry-based expression profiling system that provides a rapid whole genome comparison between test and control subjects, providing data even about as yet uncharacterized genes.

GeneXP Biosciences Inc.

The managers of GeneXP Biosciences think the global views of gene expression afforded by Affymetrix's microarray chips have their limitations--too much information. GeneXP aims to serve researchers who are ready to focus on specific gene sets. It will sell companies the tools and equipment they need to do high-throughput gene expression studies--or do the work for them.

Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts